Dermavant Moves One Step Closer to Potential New Treatment Option for Patients with Plaque Psoriasis


Sponsored Content

Partner Perspectives

Click here for the NDA acceptance press release

Dermavant Sciences recently announced that the FDA accepted for filing a New Drug Application (NDA) for tapinarof for the treatment of plaque psoriasis in adult patients. Tapinarof is an investigational novel, therapeutic aryl hydrocarbon receptor modulating agent, in development as a once-daily, steroid-free and cosmetically elegant topical cream for the treatment of plaque psoriasis and atopic dermatitis. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date in Q2 2022.

Message from Dermavant CEO, Todd Zavodnick

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.